Health and Healthcare
Biotech Busine$$ Daily (BNT, TEVA, BPAX, NCST, RPRX, VRTX)
Published:
Last Updated:
Bentley Pharmaceuticals Inc. (NYSE: BNT) will be purchased by Teva Pharmaceutical Industries (NASDAQ: TEVA) for $360 million. Bentley shareholders will receive $15 per share and an undisclosed amount of shares in CPEX Pharmaceuticals, a drug-delivery Bentley spin-off. Bentley sells about 130 products in Spain and the transaction will allow Teva to meet its strategic Spain target. Bentley is up 15% to $15.70 on a 52-week range of $8.06 to $15.89. Teva is up marginally, almost 2% to $46.81 on the announcement. Their 52-week range is $35.90 to $50.00.
BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) announced Friday they are to begin Phase III late stage studies for their “Viagra for Women” treatment, LibiGel, which attempts to remedy a loss of libido in women. Shares are not stimulated, down by $0.55, a 12% drop, to $4.13. The 52-week range is $2.05 to $8.00.
Nucryst Pharmaceuticals Corporation (NASDAQ: NCST) up over by over $0.60, a whopping 60% jump, to $1.64 in mid-day trading on new news. Friday, the stock dropped $0.50 to a new 52-week low. This volatile infection and inflammation biotech company has a 52-week range of $1.01 to $1.85.
Repros Therapeutics (NASDAQ: RPRX) reported some interim safety results from its ongoing One-Year open label study of its Proellex(R) for the indicated treatment of uterine fibroids. Its shares are up 2.4% today. We just covered this one in our weekly "10 Stocks Under $10" subscriber newsletter this morning ahead of the news. It’s still under that $10.00 threshold, for now.
Vertex Pharmaceuticals Inc. (VRTX) and their hepatitis C competitor, Schering-Plough, released clinical data on their respective drugs today. Schering-Plough’s drug, boceprevir, did not stack up to Vertex’s previously presented similar clinical data, hinting that Schering-Plough may not be as big as a competitor in the market as previously expected. Paired with positive results on Vertex’s drug, the stock is up almost 20% to $22.34 in mid-day trading. The 52-week range is $19.99 to $22.61.
Rachel Lopez
March 31, 2008
The Average American Is Losing Momentum On Their Savings Every Day (Sponsor)
If you’re like many Americans and keep your money ‘safe’ in a checking or savings account, think again. The average yield on a savings account is a paltry .4%1 today. Checking accounts are even worse.
But there is good news. To win qualified customers, some accounts are paying more than 7x the national average. That’s an incredible way to keep your money safe and earn more at the same time. Our top pick for high yield savings accounts includes other benefits as well. You can earn up to 4.00% with a Checking & Savings Account today Sign up and get up to $300 with direct deposit. No account fees. FDIC Insured.
Click here to see how much more you could be earning on your savings today. It takes just a few minutes to open an account to make your money work for you.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.
You can follow him investing $500,000 of his own money on our top AI stocks for free.